Treatment of chronic hepatitis C in a Canadian Aboriginal population: Results from the PRAIRIE study

Canadian Journal of Gastroenterology

Volumn 27, Issue 12, 2013, Pages 707-710

  Minuk, Gerald Yosel ^a   O'Brien, Meaghan ^a   Hawkins, Kim ^a   Emokpare, Didi ^b   McHattie, James ^b   Harris, Paul ^b   Worobetz, Lawrence ^b   Doucette, Karen ^c   Kaita, Kelly ^a   Wong, Stephen ^a   Pinette, Gilles ^a   Uhanova, Julia ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aboriginal; Ethnicity; First Nations; Hepatitis; Hepatitis C; Interferon; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; BILIRUBIN; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VIRUS RNA;

ABORIGINE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASCITES; CAUCASIAN; CLINICAL TRIAL (TOPIC); COUGHING; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LICHEN PLANUS; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; MIGRAINE; NEUTROPENIA; PRIORITY JOURNAL; RETINOPATHY; SIDE EFFECT; SUICIDE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD; WEAKNESS; WEIGHT REDUCTION;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INUITS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84890261906     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/963694     Document Type: Article

References (17)

1. Statistics Canada. Aboriginal identity population by age groups. 2006 Census data. http://www12.statcan.ca/census-recensement/2006/dp-pd/hlt/97-558/ pages/page.cfm?Lang=E&Geo=PR&Code=01&Table=1&Data=Count&Sex= 1&Age=1&StartRec=1&Sort=5&Display=Page&CSDFilter=250 (Accessed July, 17, 2013).
2. Remis RS. Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007. Final Report. HP40-39/2009E-PDF;978-1-100- 12614-2. 〈www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng. pdf〉 (Accessed August 1, 2013).
3. Minuk GY, Uhanova J. Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 2003;17:707-12.
4. Minuk GY, Zhang M, Wong SG, et al. Viral hepatitis in a Canadian First Nations community. Can J Gastroenterol 2003;17:593-6.
5. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007;21:447-51.
6. Dawood M, Smart G, Wood M, Wu HX, Paton S, Wu J. Hepatitis C virus infection among First Nation and non-First Nation people in Manitoba, Canada: A public health laboratory study. Can J Microbiol 2006;52:99-1005.
7. Rempel JD, Aborsangaya KB, Alphonse MP, Minuk GY. The influence of North American Aboriginal ethnicity on pro-inflammatory and anti-inflammatory cytokine responses to IFN-alpha. J Viral Hepat 2009;16:292-7.
8. [No authors listed]. Canadian consensus conference on the management of viral hepatitis. Canadian Association for the Study of the Liver. Can J Gastroenterol 2000;(14 Suppl B):5B-20B.
9. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75.
10. Spaan M, Janssen HL, Boonstra A. Immunology of hepatitis C virus infections. Best Pract Res Clin Gastroenterol 2012;26:391-400.
11. Civeira MP, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999;(31 Suppl 1):237-43.
12. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000;7:250-7.
13. Lo Re V III, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: A cohort study. Ann Intern Med 2011;155:353-60.
14. Cooper CL, Bailey RJ, Bain VG, et al Canadian Pegasys Study Group. Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol 2008;22:677-80.
15. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;35(5 Suppl 1):S220-5.
16. MacMillan HL, MacMillan AB, Offord DR, Dingle JL. Aboriginal health. CMAJ 1996;155:1569-78.
17. Sugiyama M, Tanaka Y, Nakanishi M, Mizokami M. Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C. J Pharmacol Sci 2011;115:263-9.